vs
ICU MEDICAL INC（ICUI）与SouthState Bank Corp（SSB）财务数据对比。点击上方公司名可切换其他公司
SouthState Bank Corp的季度营收约是ICU MEDICAL INC的1.2倍（$661.7M vs $540.7M），SouthState Bank Corp净利率更高（34.1% vs -2.9%，领先37.0%），过去两年SouthState Bank Corp的营收复合增速更高（37.4% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
SouthState Bank总部位于美国佛罗里达州温特黑文，是银行控股公司SouthState Corporation旗下的银行子公司。截至2025年5月26日，该行已在南卡罗来纳、北卡罗来纳、佐治亚、佛罗里达、阿拉巴马、弗吉尼亚、科罗拉多、得克萨斯八州设有371家营业网点，为当地客户提供各类银行金融服务。
ICUI vs SSB — 直观对比
营收规模更大
SSB
是对方的1.2倍
$540.7M
净利率更高
SSB
高出37.0%
-2.9%
两年增速更快
SSB
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $661.7M |
| 净利润 | $-15.7M | $225.8M |
| 毛利率 | 37.5% | — |
| 营业利润率 | 1.0% | 15.1% |
| 净利率 | -2.9% | 34.1% |
| 营收同比 | -14.1% | — |
| 净利润同比 | 34.0% | 153.5% |
| 每股收益（稀释后） | $-0.63 | $2.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUISSB
| Q1 26 | — | $661.7M | ||
| Q4 25 | $540.7M | $581.1M | ||
| Q3 25 | $537.0M | $599.7M | ||
| Q2 25 | $548.9M | $577.9M | ||
| Q1 25 | $604.7M | $544.5M | ||
| Q4 24 | $629.8M | $369.8M | ||
| Q3 24 | $589.1M | $351.5M | ||
| Q2 24 | $596.5M | $350.3M |
净利润ICUISSB
| Q1 26 | — | $225.8M | ||
| Q4 25 | $-15.7M | $247.7M | ||
| Q3 25 | $-3.4M | $246.6M | ||
| Q2 25 | $35.3M | $215.2M | ||
| Q1 25 | $-15.5M | $89.1M | ||
| Q4 24 | $-23.8M | $144.2M | ||
| Q3 24 | $-33.0M | $143.2M | ||
| Q2 24 | $-21.4M | $132.4M |
毛利率ICUISSB
| Q1 26 | — | — | ||
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 37.9% | — | ||
| Q1 25 | 34.7% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 34.8% | — | ||
| Q2 24 | 34.8% | — |
营业利润率ICUISSB
| Q1 26 | — | 15.1% | ||
| Q4 25 | 1.0% | 54.3% | ||
| Q3 25 | 2.6% | 53.6% | ||
| Q2 25 | 1.9% | 48.8% | ||
| Q1 25 | 2.1% | 22.3% | ||
| Q4 24 | 6.0% | 50.7% | ||
| Q3 24 | 1.4% | 53.1% | ||
| Q2 24 | 1.3% | 49.3% |
净利率ICUISSB
| Q1 26 | — | 34.1% | ||
| Q4 25 | -2.9% | 42.6% | ||
| Q3 25 | -0.6% | 41.1% | ||
| Q2 25 | 6.4% | 37.2% | ||
| Q1 25 | -2.6% | 16.4% | ||
| Q4 24 | -3.8% | 39.0% | ||
| Q3 24 | -5.6% | 40.7% | ||
| Q2 24 | -3.6% | 37.8% |
每股收益（稀释后）ICUISSB
| Q1 26 | — | $2.28 | ||
| Q4 25 | $-0.63 | $2.47 | ||
| Q3 25 | $-0.14 | $2.42 | ||
| Q2 25 | $1.43 | $2.11 | ||
| Q1 25 | $-0.63 | $0.87 | ||
| Q4 24 | $-0.97 | $1.88 | ||
| Q3 24 | $-1.35 | $1.86 | ||
| Q2 24 | $-0.88 | $1.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $2.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $9.0B |
| 总资产 | $4.1B | $68.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUISSB
| Q1 26 | — | $2.9B | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $308.6M | — | ||
| Q3 24 | $312.5M | — | ||
| Q2 24 | $302.6M | — |
股东权益ICUISSB
| Q1 26 | — | $9.0B | ||
| Q4 25 | $2.1B | $9.1B | ||
| Q3 25 | $2.1B | $9.0B | ||
| Q2 25 | $2.1B | $8.8B | ||
| Q1 25 | $2.0B | $8.6B | ||
| Q4 24 | $2.0B | $5.9B | ||
| Q3 24 | $2.0B | $5.9B | ||
| Q2 24 | $2.0B | $5.7B |
总资产ICUISSB
| Q1 26 | — | $68.0B | ||
| Q4 25 | $4.1B | $67.2B | ||
| Q3 25 | $4.1B | $66.0B | ||
| Q2 25 | $4.1B | $65.9B | ||
| Q1 25 | $4.2B | $65.1B | ||
| Q4 24 | $4.2B | $46.4B | ||
| Q3 24 | $4.3B | $46.1B | ||
| Q2 24 | $4.3B | $45.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | — |
| 自由现金流经营现金流 - 资本支出 | $36.0M | — |
| 自由现金流率自由现金流/营收 | 6.6% | — |
| 资本支出强度资本支出/营收 | 4.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUISSB
| Q1 26 | — | — | ||
| Q4 25 | $60.6M | $232.1M | ||
| Q3 25 | $56.7M | $122.4M | ||
| Q2 25 | $11.2M | $72.6M | ||
| Q1 25 | $51.3M | $-126.3M | ||
| Q4 24 | $40.2M | $354.3M | ||
| Q3 24 | $36.1M | $-246.8M | ||
| Q2 24 | $82.0M | $126.8M |
自由现金流ICUISSB
| Q1 26 | — | — | ||
| Q4 25 | $36.0M | $215.5M | ||
| Q3 25 | $27.6M | $101.7M | ||
| Q2 25 | $-8.5M | $52.5M | ||
| Q1 25 | $36.7M | $-139.1M | ||
| Q4 24 | $16.1M | $340.9M | ||
| Q3 24 | $16.2M | $-254.2M | ||
| Q2 24 | $62.5M | $117.3M |
自由现金流率ICUISSB
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 37.1% | ||
| Q3 25 | 5.1% | 17.0% | ||
| Q2 25 | -1.5% | 9.1% | ||
| Q1 25 | 6.1% | -25.5% | ||
| Q4 24 | 2.6% | 92.2% | ||
| Q3 24 | 2.7% | -72.3% | ||
| Q2 24 | 10.5% | 33.5% |
资本支出强度ICUISSB
| Q1 26 | — | — | ||
| Q4 25 | 4.6% | 2.9% | ||
| Q3 25 | 5.4% | 3.5% | ||
| Q2 25 | 3.6% | 3.5% | ||
| Q1 25 | 2.4% | 2.4% | ||
| Q4 24 | 3.8% | 3.6% | ||
| Q3 24 | 3.4% | 2.1% | ||
| Q2 24 | 3.3% | 2.7% |
现金转化率ICUISSB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.94× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | 0.32× | 0.34× | ||
| Q1 25 | — | -1.42× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | -1.72× | ||
| Q2 24 | — | 0.96× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
SSB
| Net Interest Income | $561.6M | 85% |
| Noninterest Income | $100.1M | 15% |
